Autor: |
Hou C; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China., Chen WX; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China., Qiu W; Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China., Li XJ; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China., Tian Y; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China., Zhu HX; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China., Zeng YR; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China., Liang HC; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China., Peng BW; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China., Chen LF; Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou 510120, China. |
Abstrakt: |
Objective: To investigate the clinical characteristics, treatment and prognosis of myelin oligodendrocyte glycoprotein antibody-associated optic neuritis (MOG-ON) in pediatric patients. Methods: Clinical data, laboratory examination, the initial best corrected visual acuity (BCVA), fundus, neuroelectrophysiological results, MRI imaging, treatment and prognosis of children diagnosed with MOG-ON from 2016 to 2019 were retrospectively analyzed. Results: A total of 29 eyes from 16 children were involved, with a male/female ratio of 1∶1, onset age of (7.0±2.9) years. Seven of 16 patients had prodromal infection, with a unilateral/bilateral ratio of 3∶13, and 2 cases had recurrent optic neuritis. Before treatment, BCVA of 19 eyes (65.5%) was ≤0.1, among them, 4 had no sense of light, 5 had light sense, 5 with sense of hands in front of eyes, and 5 with sense of fingers in front of eyes. There were 10 eyes (34.5%) with BCVA of 0.1-0.5. After treatment, there were 4 eyes (13.8%), 5 eyes (17.2%) and 20 eyes (69.0%) in groups with BCVA of 0.1-0.5, 0.5-1.0, and>1.0, respectively. Twelve of 16 patients had optic papillitis in fundus examination during acute phase. The latency was prolonged and the amplitude was decreased in P100 wave of all the children. Thirteen out of 16 children showed swelling and thickening of optic nerve in MRI T2WI. MRI images exhibited intracranial demyelinating lesions in 12 of 16 children and long segment spinal cord lesions in 3 of 16 children. Thirteen of 16 patients showed effective results after intravenous methylprednisolone (IVMP) and intravenous immunoglobulin (IVIG) treatment. There was no relapse after administration of mycophenolate mofetil in 2 recurrent children. No progression after administration of rituximab was found in 1 child with corticosteroid insensitivity. The average follow-up time was (16±9) months and no recurrence occurred. Ten of 16 patients had full recovery, 4 had significant improvement, and 2 showed no significant improvement. Conclusions: There is no significant gender difference in the incidence of pediatric MOG-ON. Bilateral involvement and severe visual impairment are common in acute phase. Most patients have good response to IVMP combined with IVIG treatment and hence have a good prognosis. Only a few of them have neurological sequelae. |